Page 151 - 2021_07-Haematologica-web

Hematopoietic JAK 2V617F in aortic aneurysms
comparison. Further studies are, thus, needed to validate our findings in larger cohorts.
In conclusion, AA are a possible vascular complication of MPN and hematopoietic JAK2 V617F may causally be involved in the development of AA through macrophage accumulation and MMP activation. The present study also provides novel mechanisms underlying the patho- genesis of AA. Hematopoietic JAK-STAT signaling may be a potential therapeutic target for the development of AA.
Contributions
TY and TM designed the research, performed experiments, analyzed the results, and wrote the manuscript; YK, KW, and KM performed the experiments and analyzed the results; KS and TI interpreted the results and supervised the study; SM and NK analyzed the results and interpreted the results, and super- vised the study; KI designed and supervised the research, ana- lyzed the data, and wrote the manuscript; YT designed and supervised the research, and approved the final version of the manuscript.
Disclosures
TY and KS have received financial support from Janssen Pharmaceutical K.K., Japan; TM has received financial support from Fukuda Denshi Co., Ltd., Japan; Ruxolitinib was provided by Novartis Pharmaceuticals to KI; these companies are, how- ever, not associated with the contents of this study; all other authors declare no conflicts of interest.
Acknowledgments
The authors thank Ms Tomiko Miura and Ms Shoko Sato, from the Department of Cardiovascular Medicine, Fukushima Medical University, Japan, and Ms Chisato Kubo, from the Office for Gender Equality Support, Fukushima Medical University, Japan, for their technical assistance, as well as Prof. Kazuya Shimoda and Dr. Kotaro Shide, from the Department of Gastroenterology and Hematology, University of Miyazaki, Japan, for providing us with JAK2V617F mice.
Funding
This work was supported by JSPS KAKENHI (grant number: JP19K17532) to TY.
References
1.Kutti J and Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis. Pathol Biol (Paris). 2001;49(2):164-166.
2. Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myelopro- liferative neoplasms and myelodysplas- tic/myeloproliferative neoplasms in the United States, 2001-12. Br J Haematol. 2016;174(3):382-396.
3.Barbui T, Finazzi G and Falanga A. Myeloproliferative neoplasms and throm- bosis. Blood. 2013;122(13):2176-2184.
4. De Stefano V, Ghirardi A, Masciulli A, et al. Arterial thrombosis in Philadelphia-nega- tive myeloproliferative neoplasms predicts second cancer: a case-control study. Blood. 2020;135(5):381-386.
5. Hultcrantz M, Björkholm M, Dickman PW, et al. Risk for arterial and venous thrombo- sis in patients with myeloproliferative neo- plasms: a population-based cohort study. Ann Intern Med. 2018;168(5):317-325.
6. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106(4):1207-1209.
7.Shide K, Shimoda HK, Kumano T, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia. 2008;22(1):87-95.
8.Shide K. The role of driver mutations in myeloproliferative neoplasms: insights from mouse models. Int J Hematol. 2020;111(2):206-216.
9. Wanhainen A, Verzini F, Van Herzeele I, et al. Editor's choice - European Society for Vascular Surgery (ESVS) 2019 clinical prac- tice guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg. 2019;57(1):8-93.
10. Wanhainen A, Hultgren R, Linne A, et al. Outcome of the swedish nationwide abdominal aortic aneurysm screening pro- gram. Circulation. 2016;134(16):1141-1148.
11. Oliver-Williams C, Sweeting MJ, Turton G, et al. Lessons learned about prevalence and growth rates of abdominal aortic
aneurysms from a 25-year ultrasound pop- ulation screening programme. Br J Surg. 2018;105(1):68-74.
12. Gunnarsson K, Wanhainen A, Björck M, Djavani-Gidlund K and Mani K. Nationwide study of ruptured abdominal aortic aneurysms during twenty years (1994-2013). Ann Surg. 2019 Aug 14. [Epub ahead of print]
13.Dale MA, Ruhlman MK and Baxter BT. Inflammatory cell phenotypes in AAAs: their role and potential as targets for thera- py. Arterioscler Thromb Vasc Biol. 2015;35(8):1746-1755.
14.Shimizu K, Mitchell RN and Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26(5): 987-994.
15. Dutta P, Courties G, Wei Y, et al. Myocardial infarction accelerates athero- sclerosis. Nature. 2012;487(7407):325-329.
16. Moazzami K, Lima BB, Hammadah M, et al. Association between change in circulat- ing progenitor cells during exercise stress and risk of adverse cardiovascular events in patients with coronary artery disease. JAMA Cardiol. 2020;5(2):147-155.
17.Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombo- sis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-5133.
18. Harada-Shirado K, Ikeda K, Ogawa K, et al. Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A pro- moter in myeloproliferative neoplasms. Br J Haematol. 2015;168(3):338-349.
19.Ueda K, Ikeda K, Ikezoe T, et al. Hmga2 collaborates with JAK2V617F in the devel- opment of myeloproliferative neoplasms. Blood Adv. 2017;1(15):1001-1015.
20. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM and Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A. 1992;89(10):4471-4475.
21. Okabe M, Ikawa M, Kominami K, Nakanishi T and Nishimune Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 1997;407(3):313-319.
22.Misaka T, Suzuki S, Miyata M, et al. Deficiency of senescence marker protein 30 exacerbates angiotensin II-induced cardiac remodelling. Cardiovasc Res. 2013;99(3): 461-470.
23. Ortega R, Collado A, Selles F, et al. SGLT-2 (Sodium-Glucose Cotransporter 2) inhibi- tion reduces ang II (Angiotensin II)-induced dissecting abdominal aortic aneurysm in ApoE (Apolipoprotein E) knockout mice. Arterioscler Thromb Vasc Biol. 2019;39(8): 1614-1628.
24. Patel J, Douglas G, Kerr AG, Hale AB and Channon KM. Effect of irradiation and bone marrow transplantation on angiotensin II-induced aortic inflammation in ApoE knockout mice. Atherosclerosis. 2018;276:74-82.
25. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myelopro- liferative neoplasms. Blood. 2010;115(15): 3109-3117.
26. Lee S, Shah T, Yin C, et al. Ruxolitinib sig- nificantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediasti- nal B-cell lymphoma and survival in a lym- phoma xenograft murine model. Oncotarget. 2018;9(11):9776-9788.
27. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/ SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121(13):e266-369.
28. Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous throm- bosis in WHO-defined essential thrombo- cythemia: an international study of 891 patients. Blood. 2011;117(22):5857-5859.
29. Barbui T, Tefferi A, Vannucchi AM, et al.
haematologica | 2021; 106(7)
1921